The FDA on June 26 granted Boehringer Ingelheim and Eli Lilly and Company’s drug empagliflozin Fast Track designation for the treatment of chronic heart failure, the companies announced.

Sportswear brand Under Armour filed a patent application this week for a new “smart” shoe that’s able to take a wearer’s blood pressure and help them recover faster from a workout.

Patients prescribed statins for CV risk reduction are more than twice as likely to develop type 2 diabetes compared to non-statin users, a study out of Ohio State University has found.

San Francisco will be the first city in the U.S. to ban the sale and distribution of e-cigarettes, NPR reported Tuesday—a significant move considering the nation’s biggest producer of e-cigs, Juul Labs, is based in the city.

Four universities were awarded research grants by the American Heart Association on June 24, each set to receive more than $3.7 million for a range of studies focused on arrhythmias and sudden cardiac arrest.

Researchers at Kazan Federal University in Russia are in the process of testing biodegradable plant-based implants that might one day replace artificial prostheses, eliminating the need for repeat surgeries as a patient’s vasculature evolves.

Two days of debate over the safety of paclitaxel-coated and -eluting devices have culminated in a nonbinding recommendation by the FDA to continue sales of such devices for PAD patients, though the agency is also urging regulators to push for better long-term clinical data than is currently available.

The Cardiovascular Research Foundation is partnering with VEITHsymposium, one of the largest annual meetings in vascular medicine, to enhance conference material at both VEITHsymposium and the CRF’s yearly Transcatheter Cardiovascular Therapeutics conference, the groups announced June 20.